Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control (FIMARO)

Boryung

Status: Completed

Conditions: Hyperlipidemias; Cardiovascular Diseases

Study type: Observational

Funder types: Industry

Identifiers

NCT02913794

BR-FMS-OS-402

Details and patient eligibility

About

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Enrollment: 541 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
• Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
• Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration

Exclusion criteria

• Patients being hospitalized
• Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
• Patients who have more than 400mg/dl triglyceride(TG) at the registration time